Targeted metabolomics detects a putatively diagnostic signature in plasma and dried blood spots from head and neck paraganglioma patients

Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma. N. Engl J Med. 2019;381:552–65.

Article  CAS  PubMed  Google Scholar 

Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33:90–114.

Article  CAS  PubMed  Google Scholar 

Pereira BD, Luiz HV, Ferreira AG, Portugal J Genetics of pheochromocytoma and paraganglioma. In: Paraganglioma: a multidisciplinary approach. Codon Publications, 2019, pp 1–22.

Guha A, Musil Z, Vicha A, Zelinka T, Pacak K, Astl J, et al. A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas. Neoplasma. 2019;66:671–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonio K, Valdez MMN, Mercado-Asis L, Taïeb D, Pacak K. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020;9:105–23.

Article  PubMed  PubMed Central  Google Scholar 

Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019;285:187–204.

CAS  PubMed  Google Scholar 

Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3:1204–12.

Article  PubMed  PubMed Central  Google Scholar 

Cleere EF, Martin-Grace J, Gendre A, Sherlock M, O’Neill JP. Contemporary management of paragangliomas of the head and neck. Laryngoscope Investig Otolaryngol. 2022;7:93–107.

Article  PubMed  Google Scholar 

Prasad SC, Paties CT, Pantalone MR, Mariani-Costantini R, Sanna M Carotid body and vagal paragangliomas: epidemiology, genetics, clinicopathological features, imaging, and surgical management. In: Paraganglioma: a multidisciplinary approach. Codon Publications, 2019, pp 81–98.

Prasad SC, Paties CT, Schiavi F, Esposito DL, Lotti LV, Mariani-Costantini R et al. Tympanojugular paragangliomas: surgical management and clinicopathological features. In: Paraganglioma: a multidisciplinary approach. Codon Publications, 2019, pp 99–123.

Prasad SC, Mimoune HA, D’Orazio F, Medina M, Bacciu A, Mariani-Costantini R, et al. The role of wait-and-scan and the efficacy of radiotherapy in the treatment of temporal bone paragangliomas. Otol Neurotol. 2014;35:922–31.

Article  PubMed  Google Scholar 

Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler JR, et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev. 2014;35:795.

Article  PubMed  PubMed Central  Google Scholar 

Lassen-Ramshad Y, Ozyar E, Alanyali S, Poortmans P, van Houtte P, Sohawon S, et al. Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study. Head Neck. 2019;41:1770–6.

Article  PubMed  Google Scholar 

Roll W, Müther M, Sporns PB, Zinnhardt B, Suero Molina E, Seifert R, et al. Somatostatin receptor-targeted radioligand therapy in head and neck paraganglioma. World Neurosurg. 2020;143:e391–e399.

Article  PubMed  Google Scholar 

Jha A, Taïeb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, et al. High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2021;27:2989–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plouin PF, Amar L, Dekkers OM, Fassnach M, Gimenez-Roqueplo AP, Lenders JWM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174:G1–G10.

Article  CAS  PubMed  Google Scholar 

Parisien S, Salle L, Chbat J, Lacroix A, Perrotte P, Karakiewicz P, et al. Postoperative recurrences in patients operated for pheochromocytomas and paragangliomas: new data supporting lifelong surveillance. Cancers. 2022;14:2942.

Article  Google Scholar 

Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23:1995–2019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43:199–239.

Article  PubMed  Google Scholar 

Richter S, Qiu B, Ghering M, Kunath C, Constantinescu G, Luths C, et al. Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer. 2022;29:213–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itani M, Mhlanga J. Imaging of pheochromocytoma and paraganglioma. In: Paraganglioma: a multidisciplinary Approach. Codon Publications, 2019, pp 41–61.

Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1443.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Jong WHA, Graham KS, Van Der Molen JC, Links TP, Morris MR, Ross HA, et al. Plasma free metanephrine measurement using automated online solid-phase extraction HPLC–tandem mass spectrometry. Clin Chem. 2007;53:1684–93.

Article  PubMed  Google Scholar 

Peitzsch M, Prejbisz A, Kroiß M, Beuschlein F, Arlt W, Januszewicz A, et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: Utility for diagnosis of dopamineproducing metastatic phaeochromocytoma. Ann Clin Biochem. 2013;50:147–55.

Article  CAS  PubMed  Google Scholar 

März J, Kurlbaum M, Roche-Lancaster O, Deutschbein T, Peitzsch M, Prehn C, et al. Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors. Front Endocrinol (Lausanne). 2021;12:722656.

Article  PubMed  Google Scholar 

Erlic Z, Kurlbaum M, Deutschbein T, Nölting S, Prejbisz A, Timmers H, et al. Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. Eur J Endocrinol. 2019;181:647–57.

Article  CAS  PubMed  Google Scholar 

Moat SJ, George RS, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. Int J Neonatal Screen. 2020;6:26.

Article  PubMed  PubMed Central  Google Scholar 

Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem. 2014;67:73–150.

Article  CAS  PubMed  Google Scholar 

He L, Cai X, Cheng S, Zhou H, Zhang Z, Ren J, et al. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett. 2019;17:5030–8.

CAS  PubMed  PubMed Central  Google Scholar 

Guo Y, Xiao Z, Yang L, Gao Y, Zhu Q, Hu L, et al. Hypoxia-inducible factors in hepatocellular carcinoma. Oncol Rep. 2020;43:3–15.

CAS  PubMed  Google Scholar 

Jung MK, Okekunle AP, Lee JE, Sung MK, Lim YJ. Role of branched-chain amino acid metabolism in tumor development and progression. J Cancer Prev. 2021;26:237–43.

Article  PubMed  PubMed Central  Google Scholar 

Wang T, Yao W, He Q, Shao Y, Zheng R, Huang F. L-leucine stimulates glutamate dehydrogenase activity and glutamate synthesis by regulating mTORC1/SIRT4 pathway in pig liver. Anim Nutr. 2018;4:329–38.

Article  PubMed  Google Scholar 

Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2021;184:2256.

Article  PubMed  Google Scholar 

Vaidya A, Flores SK, Cheng Z-M, Nicolas M, Deng Y, Opotowsky AR, et al. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. N. Engl J Med. 2018;378:1259–61.

Article  PubMed  PubMed Central  Google Scholar 

Corbet C, Draoui N, Polet F, Pinto A, Drozak X, Riant O, et al. The SIRT1/HIF2α axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. Cancer Res. 2014;74:5507–19.

Article  CAS  PubMed  Google Scholar 

Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52:1496–516. 2020 529.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorendeau D, Rinaldi G, Boon R, Spincemaille P, Metzger K, Jäger C, et al. Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors. Metab Eng. 2017;43:187–97.

Article  CAS  PubMed  Google Scholar 

Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM, et al. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat Commun. 2013;4:1–11.

Article  Google Scholar 

Sarkadi B, Meszaros K, Krencz I, Canu L, Krokker L, Zakarias S, et al. Glutaminases as a novel target for sdhb-associated pheochromocytomas/paragangliomas. Cancers. 2020;12:599.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blackburn PR, Hickey RD, Nace RA, Giama NH, Kraft DL, Bordner AJ, et al. Silent tyrosinemia type i without elevated tyrosine or succinylacetone associated with liver cirrhosis and hepatocellular carcinoma. Hum Mutat. 2016;37:1097–105.

留言 (0)

沒有登入
gif